Osimertinib for NSCLC With Uncommon EGFR Mutations

Sponsor
Sheba Medical Center
Study ID
NCT05421936
Status
Suspended

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Genes, erbB-1

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a multi-center, retrospective study of ucEGFRmut (exon 20 insertions excluded) metastatic NSCLC osimertinib-treated as first EGFR inhibitor. RECIST and RANO-BM brain objective response rate (ORR) were evaluated by investigators. mPFS, mOS and mDOR were calculated from osimertinib initiation. Mutations found at resistance were collected.

Key Dates

Start date
Sep 27, 2020
Status verified
Nov 2023
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

Progression free survival [ Time Frame: From date of osimertinib initiation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months ]

Related Studies